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I n this study of Medicare claims (2007–2014) from olderindividuals with type 2 diabetes, Landon et al.1 highlight a
mix of encouraging and discouraging findings. One caveat in
interpreting their findings is that diabetes treatment guidelines
are consensus-based,2,3 and we often do not know what pro-
portion of patients the guidelines apply to, or what proportion
of patients receiving particular treatments is appropriate.
Encouraging findings in the study are the increased use of
metformin as initial pharmacotherapy (from 50 to 70%), the
increased use of stains, and the decreased use of long-acting
sulfonylureas. Discouraging findings include the potential
overuse of blood glucose self-monitoring and safety concerns
related to the complexity of insulin regimens in older and
sicker individuals. Given the presumption that other regimens
might be safer and equally effective, insulin treatment in older
adults deserves particular attention in future work.
An area of uncertainty for diabetes treatment is selecting
medications to add to metformin. The ongoing GRADE ran-
domized clinical trial4 seeks to inform this decision, but until
results are available, clinicians will have to rely on choosing
agents based on side effects, cost, and patient preference, asmost
agents offer similar reductions in glycemia. An emerging con-
sideration however is cardiovascular risk reduction, particularly
seen with GLP-1 and SGLT-2 agents.5 Whether this evidence is
generalizable to individuals at lower risk than those included in
the trials (a majority of those with diabetes), and whether the
high cost of these agents is justified, remains to be seen.
Median out of pocket medication costs nearly halved during
the study period, to $105/year. However, mean costs increased
during the study period, driven by the use of expensive
medications in a small proportion of individuals. While this
study cannot determine whether that spending is justified, this
is another key area for further research.
For those studying trends in diabetes treatment, particularly
for older adults, this study offers an important snapshot of the
changing landscape. Further, it highlights questions about
complicated and expensive treatment regimens as key areas
for future study, as wemake concerted efforts to offer safer and
more effective diabetes care.
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